- Trial phase
- Approved
- Time to market
- Already approved and commercially available in the U.S. (since 2018 for adults, expanded to adolescents 12+ in February 2026) and in the EU (since 2019 for ages 16+, with a May 2026 CHMP positive opinion for further expansion).
- Why 4/10
- PALYNZIQ is already approved and commercially marketed (FDA approved May 2018 for adults, expanded to adolescents 12+ in February 2026). There is no pending PDUFA date or pivotal readout for this drug in the next ~12 months, so the next binary catalyst is absent. The drug is a meaningful but not dominant part of BioMarin's portfolio (trails VOXZOGO in revenue).
PALYNZIQ has no upcoming binary catalyst; the next major BioMarin catalysts are VOXZOGO PDUFA dates (Feb 28, 2027 for full achondroplasia approval, May 30, 2027 for hypochondroplasia). Watch Q4 2026 earnings for PALYNZIQ's post-adolescent-expansion revenue trajectory and any EMA adolescent label decision for Europe.
Price Chart
Executive Summary
PALYNZIQ (pegvaliase-pqpz) is BioMarin Pharmaceutical's enzyme substitution therapy for phenylketonuria (PKU), a rare genetic disorder. First approved by the FDA in May 2018 for adults, it received a key label expansion in February 2026 to include adolescents aged 12 and older, based on positive Phase 3 PEGASUS trial data. The drug carries a black-box warning for anaphylaxis and requires daily injections, which limits adoption versus oral alternatives. PALYNZIQ generated $135 million in Q2 2026 revenue (up 27% YoY) and is part of BioMarin's growing Metabolic Conditions portfolio, but it is not the company's largest product (VOXZOGO at $245M in Q3 2026 is bigger). With no pending regulatory catalyst for PALYNZIQ in the next 12 months, the stock's near-term binary events center on VOXZOGO PDUFA dates in early 2027.
How It Works
PALYNZIQ is an enzyme substitution therapy for phenylketonuria (PKU), a genetic disease where the body cannot break down the amino acid phenylalanine (Phe) from food. The drug replaces the missing or defective enzyme (PAH) with a lab-made enzyme (pegvaliase) that breaks down Phe in the blood, preventing toxic buildup that can cause brain damage. It is given as a daily injection under the skin.
Trial Status
PALYNZIQ is FDA-approved and commercially marketed. The pivotal Phase 3 PEGASUS trial supported the February 2026 adolescent label expansion, demonstrating statistically significant blood phenylalanine lowering versus diet alone in patients aged 12-17. Real-world evidence studies are ongoing for long-term safety monitoring.
The Two-Sided Case
Upcoming Catalysts
- Potential EMA decision on expanding PALYNZIQ label to adolescents aged 12+ in Europe (no firm date announced)
- Q4 2026 earnings report (expected February 2027) showing PALYNZIQ revenue trajectory post-adolescent expansion
- Ongoing real-world safety data readouts for adolescent patients
Source Filing
The SecBot filing or press-release report that triggered this drug report:
BIOMARIN PHARMACEUTICAL INC 8-K BMRN ·Originating report